BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15205581)

  • 1. Renal cell carcinoma - innovative medical treatments.
    Huland E; Heinzer H
    Curr Opin Urol; 2004 Jul; 14(4):239-44. PubMed ID: 15205581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinoma: novel treatments for advanced disease.
    Huland E; Heinzer H
    Curr Opin Urol; 2003 Nov; 13(6):451-6. PubMed ID: 14560137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
    Heinzer H; Huland E; Huland H
    Urologe A; 2003 Nov; 42(11):1450-2. PubMed ID: 14624342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.
    Huland E; Heinzer H; Mir TS; Huland H
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S98-105. PubMed ID: 9457403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for renal cell carcinoma.
    Motzer RJ; Russo P
    J Urol; 2000 Feb; 163(2):408-17. PubMed ID: 10647643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
    Huland E; Heinzer H; Huland H
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases].
    Heinzer H; Huland E; Huland H
    Urologe A; 2000 Jul; 39(4):356-61. PubMed ID: 10957779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.
    Fallick ML; McDermott DF; LaRock D; Long JP; Atkins MB
    J Urol; 1997 Nov; 158(5):1691-5. PubMed ID: 9334580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic renal cell cancer treatments.
    Sternberg CN
    Drugs Today (Barc); 2003; 39 Suppl C():39-59. PubMed ID: 14988745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
    Figlin RA; Abi-Aad AS; Belldegrun A; deKernion JB
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):102-7. PubMed ID: 1719641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.